1. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru.
- Author
-
Palacios E, Dallman R, Muñoz M, Hurtado R, Chalco K, Guerra D, Mestanza L, Llaro K, Bonilla C, Drobac P, Bayona J, Lygizos M, Anger H, and Shin S
- Subjects
- Adolescent, Adult, Animals, Female, Humans, Infant, Newborn, Middle Aged, Peru, Pregnancy, Retrospective Studies, Treatment Outcome, Young Adult, Antitubercular Agents therapeutic use, Pregnancy Complications, Infectious drug therapy, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) disproportionately affects young adults, including women of childbearing age; however, treatment of MDR-TB during pregnancy is still controversial. This study looks at the treatment and pregnancy outcomes in a cohort of women who were treated for MDR-TB during pregnancy during a period of 10 years., Methods: A retrospective case study was performed using a standardized data collection form and data from 3 ranked sources of patient records. All 38 participants were treated during pregnancy with individualized regimens that included second-line TB medications. We examined the frequency of favorable and adverse outcomes with regard to disease and pregnancy., Results: After completion of MDR-TB treatment, 61% of the women were cured, 13% had died, 13% had defaulted, 5% remained in treatment, and 5% had experienced treatment failure. Four of the women experienced clinical deterioration of TB during pregnancy. Five of the pregnancies terminated in spontaneous abortions, and 1 child was stillborn. Among the living newborns, 3 were born with low birth weight, 1 was born prematurely, and 1 had fetal distress., Conclusions: The rates of success in treating MDR-TB in our cohort are comparable to those of other MDR-TB treatment programs in Peru. The birth outcomes of our cohort are similar to those among the general Peru population. Therefore, we advocate that a woman should be given the option to continue treatment of MDR-TB rather than terminating pregnancy or discontinuing MDR-TB treatment.
- Published
- 2009
- Full Text
- View/download PDF